Revenue Performance: Aehr Test reported revenues of $14.1 million for Q4 2025, down from $16.6 million in Q4 2024.
- Year-over-Year Change: -15%
- Quarter-over-Quarter Change: -23%
Gross Profit Margin: Dropped to 34.7% compared to 51.5% the previous year, driven by the inclusion of InCalΓ’β¬β’s operations, product mix, and lower overall production volumes.
Profitability Metrics:
- Net Loss: $2.9 million, compared to a net income of $24.7 million in Q4 2024, which included a one-time tax benefit.
- EPS: Diluted EPS fell to -$0.10 from $0.84 in the previous year.
Cash Flow: The company ended Q4 with $26.5 million in cash and equivalents, down from $49.3 million in Q4 2024, impacted by operational cash outflows and capital expenditures, including the $11 million acquisition of InCal.
Balance Sheet Health: Aehr holds no debt, indicating a conservative capital structure, supporting further growth opportunities without leverage risks.